Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04263363 · ClinicalTrials.gov registry record · Phase 4
Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 12,248
- Enrollment target
NCT04263363: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT04263363 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 12,248 participants, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (2269% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04263363, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12,248 participants
- Enrollment target
Study Summary
The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and implement a clinical best practice pathway designed to prevent postoperative respiratory complications in higher risk patients (such as those with OSA or preexisting respiratory disease) using education and clinical decision support in patients.
Primary Outcome
The time the anesthesiologist places the discharge order
Interventions
- DRUG Sugammadex 100 MG/ML [Bridion]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,248 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 4 |
What the finished NCT04263363 record still lists
NCT04263363 is an interventional study that assigns participants to a tested intervention. Its 12,248 participants enrollment target places it among the larger protocols in the corpus, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (2269% higher).
The record links to 0 conditions, and to 1 intervention - of which Sugammadex 100 MG/ML [Bridion] is the first listed.
NCT04263363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04263363 about?
NCT04263363 is a clinical study titled "Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications". The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and i...
What is the current status of trial NCT04263363?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12,248 participants. The study started on 2022-02-18. Estimated completion is 2025-05-07.
What interventions are being tested in trial NCT04263363?
The interventions under investigation include: Sugammadex 100 MG/ML [Bridion] (DRUG).
Who is sponsoring clinical trial NCT04263363?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04263363's enrollment target sits among peer trials
12,248 7th of 2000 higher than 1,994 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI